PMC:7105881 / 31832-32208 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1039","span":{"begin":79,"end":87},"obj":"Species"},{"id":"1040","span":{"begin":188,"end":196},"obj":"Species"},{"id":"1041","span":{"begin":236,"end":244},"obj":"Species"},{"id":"1042","span":{"begin":245,"end":250},"obj":"Species"},{"id":"1054","span":{"begin":73,"end":77},"obj":"CellLine"}],"attributes":[{"id":"A1039","pred":"tao:has_database_id","subj":"1039","obj":"Tax:694009"},{"id":"A1040","pred":"tao:has_database_id","subj":"1040","obj":"Tax:694009"},{"id":"A1041","pred":"tao:has_database_id","subj":"1041","obj":"Tax:694009"},{"id":"A1042","pred":"tao:has_database_id","subj":"1042","obj":"Tax:9606"},{"id":"A1054","pred":"tao:has_database_id","subj":"1054","obj":"CVCL:5V07"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T171","span":{"begin":14,"end":18},"obj":"Body_part"},{"id":"T172","span":{"begin":90,"end":97},"obj":"Body_part"},{"id":"T173","span":{"begin":210,"end":217},"obj":"Body_part"},{"id":"T174","span":{"begin":255,"end":259},"obj":"Body_part"}],"attributes":[{"id":"A171","pred":"fma_id","subj":"T171","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A172","pred":"fma_id","subj":"T172","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A173","pred":"fma_id","subj":"T173","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A174","pred":"fma_id","subj":"T174","obj":"http://purl.org/sig/ont/fma/fma24920"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T163","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"T164","span":{"begin":188,"end":196},"obj":"Disease"},{"id":"T165","span":{"begin":236,"end":244},"obj":"Disease"}],"attributes":[{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T418","span":{"begin":14,"end":18},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T419","span":{"begin":42,"end":44},"obj":"http://purl.obolibrary.org/obo/CLO_0003358"},{"id":"T420","span":{"begin":73,"end":75},"obj":"http://purl.obolibrary.org/obo/CLO_0002878"},{"id":"T421","span":{"begin":159,"end":167},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T422","span":{"begin":245,"end":250},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T187","span":{"begin":42,"end":44},"obj":"Chemical"},{"id":"T188","span":{"begin":90,"end":97},"obj":"Chemical"},{"id":"T189","span":{"begin":210,"end":217},"obj":"Chemical"}],"attributes":[{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_91150"},{"id":"A188","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T193","span":{"begin":0,"end":376},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T518","span":{"begin":7,"end":13},"obj":"NCBITaxon:6960"},{"id":"T519","span":{"begin":19,"end":28},"obj":"GO:0010467"},{"id":"T520","span":{"begin":51,"end":64},"obj":"GO:0005576"},{"id":"T521","span":{"begin":65,"end":71},"obj":"SO:0000417"},{"id":"T522","span":{"begin":79,"end":87},"obj":"SP_10"},{"id":"T523","span":{"begin":88,"end":97},"obj":"PG_1"},{"id":"T524","span":{"begin":130,"end":140},"obj":"GO:0042571"},{"id":"T525","span":{"begin":188,"end":196},"obj":"SP_10"},{"id":"T526","span":{"begin":197,"end":207},"obj":"GO:0010467"},{"id":"T527","span":{"begin":208,"end":217},"obj":"PG_1"},{"id":"T528","span":{"begin":236,"end":244},"obj":"SP_10"},{"id":"T529","span":{"begin":245,"end":250},"obj":"SP_6;NCBITaxon:9606"},{"id":"T530","span":{"begin":255,"end":265},"obj":"SP_5"},{"id":"T55510","span":{"begin":7,"end":13},"obj":"NCBITaxon:6960"},{"id":"T48550","span":{"begin":19,"end":28},"obj":"GO:0010467"},{"id":"T6400","span":{"begin":51,"end":64},"obj":"GO:0005576"},{"id":"T82107","span":{"begin":65,"end":71},"obj":"SO:0000417"},{"id":"T79376","span":{"begin":79,"end":87},"obj":"SP_10"},{"id":"T40036","span":{"begin":88,"end":97},"obj":"PG_1"},{"id":"T30442","span":{"begin":130,"end":140},"obj":"GO:0042571"},{"id":"T88681","span":{"begin":188,"end":196},"obj":"SP_10"},{"id":"T39868","span":{"begin":197,"end":207},"obj":"GO:0010467"},{"id":"T37152","span":{"begin":208,"end":217},"obj":"PG_1"},{"id":"T62328","span":{"begin":236,"end":244},"obj":"SP_10"},{"id":"T47566","span":{"begin":245,"end":250},"obj":"SP_6;NCBITaxon:9606"},{"id":"T32795","span":{"begin":255,"end":265},"obj":"SP_5"}],"text":"Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al., 2006a)."}